La Jolla Pharmaceutical Company , a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It engages in developing LJPC-501, a formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension; and LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. The company is also developing LJPC-30S, which is the gentamicin derivative program for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.

FULL NAME*

What's Your Role?*

WORK EMAIL*

COMPANY NAME*

Company Description*

HOW'D YOU HEAR ABOUT US?

DETAILS ABOUT YOUR GOALS

La Jolla Pharmaceutical Company

10182 Telesis Court
6th Floor
San Diego, CA 92121

+1 (858) 207-4264

www.lajollapharmaceutical.com

September 2019
S M T W T F S
« Aug    
1234567
891011121314
15161718192021
22232425262728
2930  

©2019 ALIGNMT LLC | Alignment Strategy | Mergers & Acquisitions | Investor Relations

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account